Thus, inhibition of IL-8 signaling appears as an attractive potential intervention to augment the efficacy of EGFR inhibition approaches in lung cancer by preventing the establishment of EMT, and/or by reverting the phenotype of tumor cells that have undergone the EMT and became resistant to the effects of EGFR inhibitors. The gene discussed is EGFR; the disease is neoplasm.